Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has earned a consensus rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th.

CytomX Therapeutics Trading Down 5.9 %

NASDAQ:CTMX opened at $0.79 on Friday. The company has a market cap of $61.84 million, a P/E ratio of 4.65 and a beta of 1.01. CytomX Therapeutics has a twelve month low of $0.78 and a twelve month high of $5.85. The company’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CTMX. Cubist Systematic Strategies LLC raised its stake in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the period. Congress Park Capital LLC increased its holdings in shares of CytomX Therapeutics by 5.4% during the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock worth $1,435,000 after buying an additional 62,788 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of CytomX Therapeutics by 32.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after buying an additional 405,669 shares during the period. US Bancorp DE acquired a new position in CytomX Therapeutics in the third quarter valued at approximately $40,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.